No Prescription |
 |
 | ||
|
Zoladex Generic Goserelin |
|
| ||
No Prescription » Prescription Drugs 17 » Zoladex Generic Goserelin This medication is used to treat: prostate cancer endometriosis advanced breast cancer in premenopausal and perimenopausal women This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for information.Goserelin is a synthetic hormone. In men it stops the production of the hormone testosterone which may stimulate the growth of cancer cells. In women goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped hormone levels return to normal. Buy Zoladex Generic Goserelin and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Zoladex Generic Goserelin: Product Type: Prescription Drugs 17 Zoladex ( Generic Goserelin ) Zoladex (Generic Goserelin) Generic Goserelin 10.8mg Generic Goserelin Zoladex
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
